Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
78.18
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
58
59
Next >
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
June 26, 2023
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t
Via
MarketBeat
Week In Review: AstraZeneca Considers Spinning Off China Ops Into Separate Company
June 24, 2023
Deals, financings, trials and approvals for the week ending June 23.
Via
Talk Markets
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
June 23, 2023
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a
Via
Benzinga
This Is What Whales Are Betting On AstraZeneca
June 23, 2023
Via
Benzinga
AI Stocks: C3.ai, Palantir Pull Back Amid HPE, Cybersecurity, Cloud AI News
June 23, 2023
The big rally in AI stocks may finally be taking a break but the steady drumbeat in artificial intelligence news continues.
Via
Investor's Business Daily
Is AstraZeneca a Top Stock to Buy Right Now?
June 22, 2023
The pharma specialist's top-shelf clinical pipeline and product portfolio should be tremendous growth drivers in the years ahead.
Via
The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
June 21, 2023
Via
Benzinga
What Does AstraZeneca's Debt Look Like?
June 21, 2023
Via
Benzinga
European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide
June 22, 2023
The EU's drugs watchdog, the European Medicines Agency, recently raised a thyroid cancer safety signal for Novo Nordisk A/S (NYSE: NVO) drugs, including the much talked semaglutide used i
Via
Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
June 21, 2023
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...
Via
Benzinga
Why Are Pieris Pharmaceuticals Shares Tanking Today
June 21, 2023
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4...
Via
Benzinga
Spotify to Launch New Expensive Subscription Plan, Chinese Vendors Bypass US Embargo to Supply Nvidia AI Chips, Eddie Wu To Succeed Daniel Zhang As Alibaba's CEO: Today's Top Stories
June 20, 2023
Bloomberg
Via
Benzinga
2 Best Biotech Stocks to Buy Right Now
June 16, 2023
These international-based pharmaceutical companies pay market-topping dividends to shareholders.
Via
The Motley Fool
This Is What Whales Are Betting On AstraZeneca
June 07, 2023
Via
Benzinga
$100 Invested In AstraZeneca 10 Years Ago Would Be Worth This Much Today
June 05, 2023
Via
Benzinga
AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions
June 20, 2023
European drugmaker AstraZeneca plc (NASDAQ: AZN) is reportedly drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is considered an option amid mounting...
Via
Benzinga
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
June 17, 2023
Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates...
Via
Talk Markets
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
June 14, 2023
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a
Via
Benzinga
AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites
June 13, 2023
From
AstraZeneca
Via
Business Wire
Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground
June 12, 2023
For the bull run to continue we need broader market participation from SMID caps.
Via
Talk Markets
Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
June 12, 2023
From
AstraZeneca
Via
Business Wire
New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control
June 09, 2023
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e
Via
Benzinga
Netflix Gains Subs From Password Sharing Crackdown, Mark Zuckerberg Discusses AI at Latest Employee Met, Privacy Breach Risk in Nvidia's AI Technology Stirs Concern: Today's Top Stories
June 09, 2023
Financial Times
Via
Benzinga
AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder
June 09, 2023
AstraZeneca Plc (NASDAQ: AZN)
Via
Benzinga
AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes
June 09, 2023
AstraZeneca plc (NASDAQ: AZN) has entered into a
Via
Benzinga
Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon
June 09, 2023
The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t
Via
Benzinga
Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway'
June 07, 2023
Piper Sandler assumed coverage of Ionis Pharmaceuticals Inc (NASDAQ: IONS) with an Overweight rating and a
Via
Benzinga
AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients
June 05, 2023
Via
Benzinga
Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
June 05, 2023
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
June 05, 2023
From
AstraZeneca
Via
Business Wire
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
58
59
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.